# Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial

> **NCT07517640** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 45 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** furmonertinib
- **PROCEDURE:** ablation
- **RADIATION:** stereotactic body radiotherapy

## Key facts

- **NCT ID:** NCT07517640
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-02-01
- **Final completion:** 2028-08-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07517640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07517640, "Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07517640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*